Loading
Malaysia's health ministry runs the public hospitals and clinics where most cancer care is given for a nominal fee, keeps the Ministry of Health Medicines Formulary that decides which medicines its facilities use, and writes the national cancer control plan.
The Ministry of Health runs Malaysia's public health service. Its fee schedule, the Fees (Medical) Order 1982 as amended in 2017, charges a citizen RM1 for a general outpatient visit, nothing for a first specialist clinic visit on referral from a government doctor and RM5 for each specialist follow-up; a third-class inpatient pays at most RM500 per admission. In a 2016 parliamentary answer the minister gave chemotherapy charges of RM200, RM100 and RM50 per treatment in first, second and third class, and a 50% reduction in third class with no RM5 specialist registration charge for citizens aged 60 and over.
Its Pharmaceutical Services Programme keeps the Ministry of Health Medicines Formulary (Formulari Ubat KKM), which listed 1,650 preparations of 864 chemical entities in January 2025. A panel chaired by the Director General of Health decides listings, meeting three times a year; a medicine or indication outside the formulary needs special approval. The National Strategic Plan for Cancer Control Programme 2021-2025, published by the ministry's Non-Communicable Disease Section, records that gefitinib and afatinib were listed for EGFR-mutated metastatic non-small cell lung cancer after prices were negotiated under value-based medicine, and lists six ministry oncology centres giving both systemic treatment and radiotherapy.
The ministry's own website answered 403 to our requests; the facts here come from its PDFs and those of its agencies. The coordinates are a Putrajaya centroid.
Shares Clinical Research Malaysia, Institut Kanser Negara (National Cancer Institute, Malaysia), Colorectal cancer.
Shares HPV DNA testing and self-sampling, Cervical cancer, Lung cancer (all types), Breast cancer (all types).
Shares Clinical Research Malaysia, Gefitinib, Lung cancer (all types).
Shares Afatinib, Gefitinib, Colorectal cancer.
Shares HPV DNA testing and self-sampling, Cervical cancer, Breast cancer (all types), Colorectal cancer.
Shares HPV DNA testing and self-sampling, Cervical cancer, Lung cancer (all types), Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/